Specifica Announces Publication of Two Peer-Reviewed Articles

Specifica Publishes Landmark Research Demonstrating the Power of Its Generation 3 Antibody Discovery Platform

Specifica Inc., a privately held antibody engineering company, has announced the publication of two peer-reviewed scientific articles highlighting the capabilities and performance of its Generation 3 (Gen 3) Antibody Discovery Platform. Together, these publications provide both the scientific foundation for the platform and evidence of its ability to generate high-quality therapeutic antibodies that rival or exceed those discovered through traditional approaches.

Specifica has developed an innovative cloud-based antibody discovery platform that provides researchers and biotechnology companies with access to advanced antibody libraries, engineering technologies, and discovery tools. By combining sophisticated computational design with next-generation antibody libraries, the platform aims to accelerate the discovery and development of new antibody therapeutics, helping researchers bring promising treatments to patients more efficiently.

Monoclonal antibodies have become one of the most important classes of modern therapeutics. These laboratory-produced antibodies are designed to bind with high specificity to particular cells, proteins, or disease targets. By recognizing and attaching to these targets, monoclonal antibodies can help the immune system identify and attack cancer cells, neutralize viruses, or regulate disease-causing biological pathways. As a result, antibody therapies have transformed the treatment of cancer, autoimmune disorders, infectious diseases, and many other conditions. Today, monoclonal antibodies represent one of the fastest-growing segments of the global pharmaceutical industry.

The first publication, “Drug-like antibodies with high affinity, diversity and developability directly from next-generation antibody libraries,” describes the scientific principles behind Specifica’s Gen 3 platform. The paper outlines how the company designed its antibody libraries to generate antibodies that not only bind strongly to their targets but also possess the characteristics needed for successful drug development, including stability, manufacturability, and favorable therapeutic properties.

The second publication, “A pandemic-enabled comparison of discovery platforms demonstrates a naïve antibody library can match the best immune-sourced antibodies,” provides a real-world evaluation of the platform’s performance. In this study, researchers compared antibodies generated against SARS-CoV-2 using the Gen 3 platform with hundreds of antibodies reported in the scientific literature from more than 50 research laboratories worldwide. The comparison demonstrated that antibodies discovered using Specifica’s naïve antibody libraries performed at a level comparable to some of the best antibodies derived from immune sources.

These findings are particularly significant because they highlight the potential of naïve antibody libraries to produce powerful therapeutic candidates without relying on immunized animals or other immune-derived sources. Such approaches can streamline antibody discovery, reduce development timelines, and expand the range of targets that can be pursued.

According to Andrew Bradbury, Specifica co-founder and Chief Scientific Officer, the publications represent an important validation of the company’s technology.

“These two papers validate the Gen 3 platform’s best-in-class status, fulfilling the original promise of naïve antibody libraries made over 30 years ago, namely, to eliminate the use of animals or immune sources to generate powerful antibodies.”

The publication of these studies marks an important milestone for Specifica and underscores the growing role of advanced computational and library-based approaches in the future of therapeutic antibody discovery. By providing researchers with access to high-quality antibody libraries and integrated discovery tools, the Gen 3 platform has the potential to accelerate the development of new treatments and contribute to the next generation of life-saving medicines.

To read more about this see the Business Wire News Release, Specifica Validates Best-in-Class Status for in vitro Antibody Discovery Platform in Two Key Peer Reviewed Publications.